Lidocaina Cloridrato S.A.L.F.

Lidocaine, the active ingredient in Lidocaina Cloridrato S.A.L.F., is a local anesthetic presented as a sterile injectable solution for intravenous use. It provides local and regional anesthesia and is also employed in the treatment of ventricular arrhythmias in appropriate patients.

GNH USA supplies Lidocaina Cloridrato S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is used in clinical settings to achieve anesthesia or to manage cardiac rhythm disturbances. - Local anesthesia: provides rapid loss of sensation for minor surgical or diagnostic procedures. - Regional anesthesia: enables nerve block techniques for surgeries requiring extensive analgesia. - Ventricular arrhythmias: suppresses abnormal ventricular electrical activity in emergency cardiac care.

Adverse reactions may occur with lidocaine administration.

Common Side Effects: - Tingling or numbness at the injection site - Dizziness or light‑headedness - Nausea or metallic taste - Transient hypotension

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrest or severe arrhythmia - Anaphylactic or severe allergic reaction - Methemoglobinemia - Respiratory depression

Lidocaine should be used with careful clinical monitoring. - Cardiac assessment: evaluate baseline rhythm and conduction before infusion. - Blood pressure monitoring: watch for hypotension during administration. - Hypersensitivity: avoid in patients with known lidocaine allergy. - Hepatic function: use caution in severe liver impairment as metabolism may be reduced. - Elderly patients: consider dose reduction due to altered pharmacokinetics. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lidocaine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Class I anti‑arrhythmics (e.g., quinidine): may increase cardiotoxicity. - Amiodarone: can potentiate lidocaine plasma levels. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): raise systemic exposure.

Moderate Interactions (Monitor Closely): - Cimetidine: may modestly increase lidocaine concentrations. - Carbamazepine: can reduce lidocaine effectiveness by inducing metabolism. - Propofol: concurrent use may enhance central nervous system depression.